We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

106 hedge funds and large institutions have $576M invested in Coherus Oncology in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 54 increasing their positions, 21 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 21

98% more call options, than puts

Call options by funds: $6.23M | Put options by funds: $3.15M

4.98% more ownership

Funds ownership: 73.3% → 78.28% (+5%)

3% less funds holding

Funds holding: 109 → 106 (-3)

14% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 22

27% less capital invested

Capital invested by funds: $793M → $576M (-$217M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
106
Holders Change
-3
Holders Change %
-2.75%
% of All Funds
2.64%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
19
Increased
54
Reduced
21
Closed
22
Calls
$6.23M
Puts
$3.15M
Net Calls
+$3.08M
Net Calls Change
+$1.85M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$69.8M
2
UBS AM
UBS AM
Illinois
+$9.44M
3
TCIM
TIAA CREF Investment Management
New York
+$7.97M
4
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
+$6.5M
5
PHS
PFM Health Sciences
California
+$5.83M

Top Sellers

Rank Fund Capital Flow
1
JCG
JHL Capital Group
Illinois
-$14.8M
2
Millennium Management
Millennium Management
New York
-$12.8M
3
PC
PointState Capital
New York
-$8.91M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$8.01M
5
BM
Bridger Management
New York
-$6.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
LTFS
101
Ladenburg Thalmann Financial Services
Florida
$31K +$38.5K +2,000 +1,835%
PCM
102
Prelude Capital Management
New York
$17K +$19.2K +1,000 +500%
Parallax Volatility Advisers
103
Parallax Volatility Advisers
California
$10K +$14.1K +731 New
Zurich Cantonal Bank
104
Zurich Cantonal Bank
Switzerland
$9K – – –
TRCT
105
Tower Research Capital (TRC)
New York
$6K +$7.69K +400 New
Creative Planning
106
Creative Planning
Kansas
$3K +$3.85K +200 New
JCG
107
JHL Capital Group
Illinois
– -$14.8M -700,000 Closed
PC
108
PointState Capital
New York
– -$8.91M -421,300 Closed
BM
109
Bridger Management
New York
– -$6.97M -329,345 Closed
Allianz Asset Management
110
Allianz Asset Management
Germany
– -$3.98M -189,745 Closed
BG
111
Bellevue Group
Switzerland
– -$3.7M -175,000 Closed
SIM
112
Spark Investment Management
New York
– -$2.64M -124,900 Closed
VMI
113
VHCP Management II
New York
– -$2.02M -95,276 Closed
SM
114
Sabby Management
Florida
– -$1.97M -93,308 Closed
SCM
115
Sio Capital Management
New York
– -$1.35M -63,800 Closed
MWNA
116
Marshall Wace North America
New York
– -$1.33M -63,374 Closed
IBT
117
International Biotechnology Trust
United Kingdom
– -$1.31M -62,000 Closed
First Trust Advisors
118
First Trust Advisors
Illinois
– -$1.23M -58,010 Closed
Norges Bank
119
Norges Bank
Norway
– -$846K -40,000 Closed
GAM
120
Gotham Asset Management
New York
– -$769K -36,380 Closed
HI
121
HBK Investments
Texas
– -$713K -33,700 Closed
CEP
122
Chicago Equity Partners
Illinois
– -$667K -31,550 Closed
TI
123
Trexquant Investment
Connecticut
– -$319K -15,061 Closed
VFA
124
Virtus Fund Advisers
Connecticut
– -$289K -13,663 Closed
BCM
125
BlueCrest Capital Management
Jersey
– -$246K -11,628 Closed
2 3 4
5
6

CHRS Hedge Fund Activity: Q2 2017 in Review

106 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2017, worth a combined $576M — down 27% from $793M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of CHRS and 19 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 54 added.

The largest buyer was Wellington Management Group, adding an estimated $69.8M. The largest seller was JHL Capital Group, exiting entirely with an estimated $14.8M sold.

  • 106 institutional investors held Coherus Oncology (CHRS) as of Q2 2017, down from 109 in Q1 2017.
  • Funds reported $576M of Coherus Oncology stock for Q2 2017, down 27% quarter-over-quarter.
  • 19 funds opened new Coherus Oncology positions in Q2 2017 and 22 closed out, a net change of -3 holders.
  • The largest Coherus Oncology buyer in Q2 2017 was Wellington Management Group, an estimated $69.8M added.
  • The largest Coherus Oncology seller in Q2 2017 was JHL Capital Group, an estimated $14.8M sold.

Based on aggregated 13F filings for Q2 2017.